Get the Stockscreener App
22.20
0.64%
0.145
Elanco Animal Health Inc stock is traded at $22.20, with a volume of 2.38M.
It is up +0.64% in the last 24 hours and up +13.16% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$22.05
Open:
$22.45
24h Volume:
2.38M
Relative Volume:
0.34
Market Cap:
$11.02B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
55.49
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+2.17%
1M Performance:
+13.16%
6M Performance:
+134.58%
1Y Performance:
+78.82%
1-Day Range:
$21.99
$22.45
1-Week Range:
$21.18
$22.45
52-Week Range:
$8.02
$22.45
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
22.19 | 10.95B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
147.11 | 64.68B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.21 | 44.25B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.215 | 41.19B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.55 | 21.74B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
419.44 | 18.93B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Will Elanco Animal Health Incorporated (5EA) stock benefit from infrastructure billJuly 2025 Reactions & Precise Buy Zone Tips - Fundação Cultural do Pará
Elanco Animal Health Hits New 52-Week High of $22.25 - Markets Mojo
Why Elanco Animal Health Incorporated (5EA) stock stays resilientPortfolio Update Summary & Free Fast Gain Swing Trade Alerts - newser.com
News impact scoring models applied to Elanco Animal Health IncorporatedWeekly Trend Recap & Reliable Price Breakout Signals - newser.com
Elanco (ELAN) Expands Labels for Key Canine Parasiticides - GuruFocus
Poultry Antibiotic Market to See Booming Growth 2025-2032 | - openPR.com
What high frequency data says about Elanco Animal Health IncorporatedMarket Performance Recap & Verified Technical Trade Signals - newser.com
A Look at Elanco Animal Health’s Valuation After Securing FDA Emergency Use Nod for Credelio - simplywall.st
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species - PR Newswire
Is Elanco Animal Health Incorporated (5EA) stock attractive for growth fundsMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Elanco Animal Health Incorporated stock benefit from Fed rate cutsEarnings Growth Report & Trade Opportunity Analysis Reports - newser.com
Will Elanco Animal Health Incorporated stock recover faster than marketJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com
Is Elanco Animal Health Incorporated stock poised for growthJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Is Elanco Animal Health Incorporated (5EA) stock a buy on weakness2025 Short Interest & Daily Risk Controlled Trade Plans - newser.com
What Could Shift the Narrative for Elanco Animal Health Amid Analyst Optimism and New Developments - Yahoo Finance
Published on: 2025-10-26 07:40:21 - newser.com
Published on: 2025-10-26 07:30:17 - newser.com
FDA Emergency Use Nod for Credelio Might Change the Case for Investing in Elanco (ELAN) - simplywall.st
Can Elanco Animal Health Incorporated stock attract ESG investmentsJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-26 00:18:58 - newser.com
Will breakout in Elanco Animal Health Incorporated lead to full recoveryInsider Selling & Long-Term Capital Growth Ideas - newser.com
How Elanco Animal Health Incorporated stock performs in interest rate cycles2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):